Market reaction and regulatory milestone
Shares of PolyPid Ltd. (NASDAQ:PYPD) rose 11.2% on Wednesday after the U.S. Food and Drug Administration accepted the firm's New Drug Application for D-PLEX100 and placed the submission on priority review. The FDA set a Prescription Drug User Fee Act target action date of November 28, 2026, which the agency's timetable places at roughly one quarter earlier than PolyPid’s previously communicated first-quarter 2027 guidance. According to the FDA, there were no filing review issues identified at acceptance.
What priority review means
Priority review reduces the agency’s typical review window from ten months to about six months. With the FDA assigning priority review to the D-PLEX100 NDA, the timetable for an agency decision has been shortened accordingly to the PDUFA date noted above.
Commercial partnership and milestone payment
The NDA acceptance triggered a $15 million milestone payment from Azurity Pharmaceuticals. That payment completes a total of $30 million in upfront and near-term milestone payments agreed under an exclusive commercial partnership that PolyPid and Azurity signed on July 17, 2026.
Product profile and clinical data
D-PLEX100 is engineered to deliver prolonged, controlled antibacterial activity directly at a surgical site with the objective of preventing abdominal surgical site infections in patients undergoing colorectal procedures. The candidate employs PolyPid’s delivery technology to provide a continuous release of the broad-spectrum antibiotic doxycycline over a 30-day period.
In the Phase 3 SHIELD II trial, D-PLEX100 met its primary endpoint and produced a 60% relative risk reduction at the study’s secondary endpoint measuring surgical site infection incidence following abdominal colorectal surgery with large incisions.
Regulatory designation and commercial timing
The FDA previously granted D-PLEX100 Breakthrough Therapy Designation for the prevention of surgical site infections in patients undergoing elective colorectal surgery. PolyPid and its commercial partner Azurity are preparing for a potential U.S. commercial launch in early 2027, contingent on FDA approval.
Outlook
The combination of priority review status, completion of the agreed near-term milestone payment from Azurity, and the Phase 3 results frames the regulatory and near-term commercial pathway for D-PLEX100. The shortened review timeline aligns the agency decision with the late-November 2026 PDUFA target action date set by the FDA.
Summary
PolyPid’s NDA for D-PLEX100 has been accepted with priority review by the FDA, advancing the review timeline and prompting a $15 million milestone payment from Azurity that completes the near-term funding tied to their exclusive commercial agreement. Clinical data from the Phase 3 SHIELD II trial showed the product candidate met its primary endpoint and reduced surgical site infections by 60% at the secondary endpoint; the company and Azurity are preparing for a potential early-2027 U.S. launch pending approval.
Key points
- D-PLEX100 NDA accepted and placed on priority review by the FDA, with a PDUFA date of November 28, 2026.
- NDA acceptance triggered a $15 million milestone payment from Azurity, completing $30 million in upfront and near-term payments under the July 17, 2026 partnership.
- Phase 3 SHIELD II results showed the primary endpoint was achieved and a 60% relative risk reduction at the secondary endpoint for surgical site infections.
Risks and uncertainties
- Final U.S. commercial launch is contingent on FDA approval; the current timeline depends on the outcome of the priority review process.
- Commercial execution will depend on the partnership between PolyPid and Azurity and the fulfillment of regulatory and market-entry conditions.